BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33971670)

  • 1. Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor.
    Nacer DF; Liljedahl H; Karlsson A; Lindgren D; Staaf J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33971670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Liljedahl H; Karlsson A; Oskarsdottir GN; Salomonsson A; Brunnström H; Erlingsdottir G; Jönsson M; Isaksson S; Arbajian E; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
    Int J Cancer; 2021 Jan; 148(1):238-251. PubMed ID: 32745259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of m
    Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
    Front Immunol; 2021; 12():782551. PubMed ID: 34975871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.
    Li B; Huang Z; Yu W; Liu S; Zhang J; Wang Q; Wu L; Kou F; Yang L
    Neoplasia; 2021 Jul; 23(7):704-717. PubMed ID: 34139453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of TCF21 mRNA expression in patients with lung adenocarcinoma.
    Xiao J; Liu A; Lu X; Chen X; Li W; He S; He B; Chen Q
    Sci Rep; 2017 May; 7(1):2027. PubMed ID: 28515486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of microenvironment-related genes in lung adenocarcinoma.
    Tao Y; Li Y; Liang B
    Future Oncol; 2020 Aug; 16(24):1825-1837. PubMed ID: 32501723
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lung Adenocarcinoma Microenvironment Mining and Its Prognostic Merit.
    Zhao R; Ding D; Yu W; Zhu C; Ding Y
    Technol Cancer Res Treat; 2020; 19():1533033820977547. PubMed ID: 33280515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
    Gao L; Zhang L
    BMC Cancer; 2021 Jul; 21(1):849. PubMed ID: 34301211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
    Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
    BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.
    He SY; Xi WJ; Wang X; Xu CH; Cheng L; Liu SY; Meng QQ; Li B; Wang Y; Shi HB; Wang HJ; Wang ZZ
    Med Sci Monit; 2019 May; 25():3941-3956. PubMed ID: 31132294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.
    Li J; Liu X; Cui Z; Han G
    Med Sci Monit; 2020 Jun; 26():e922070. PubMed ID: 32578582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.
    Ringnér M; Staaf J
    Oncotarget; 2016 Aug; 7(33):52957-52973. PubMed ID: 27437773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
    Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
    EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.